Travere Therapeutics, Inc.
Clinical trials sponsored by Travere Therapeutics, Inc., explained in plain language.
-
New drug shows promise in slowing kidney disease for FSGS patients
Disease control CompletedThis study tested a new medicine called sparsentan in 371 people with a rare kidney disease called FSGS. The goal was to see if it could slow down kidney damage better than a standard treatment. Participants took either sparsentan or a standard blood pressure pill, and researcher…
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:39 UTC
-
New drug combo shows promise for slowing kidney disease
Disease control CompletedThis study tested whether adding the drug sparsentan to a standard SGLT2 inhibitor can safely reduce protein leakage in the urine of adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The 48 participants had already been on stable doses of both an SGLT…
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:38 UTC